Neutralisation titres against SARS-CoV-2 are sustained 6 months after onset of symptoms in individuals with mild COVID-19
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Dokumenter
- Neutralisation titres against SARS-CoV-2 are sustained 6 months after onset of symptoms in individuals with mild COVID-19
Forlagets udgivne version, 1,75 MB, PDF-dokument
Background: Given the importance of neutralising antibodies in protection against SARS-CoV-2 infection, it is critical to assess neutralisation persistence long-term following recovery. This study investigated neutralisation titres against SARS-CoV-2 up to 6 months post-symptom onset in individuals with mild COVID-19. Methods: Plasma neutralisation titres in convalescent COVID-19 individuals were determined at baseline and 6 months post-symptom onset using a cell culture infectious SARS-CoV-2 assay. Total SARS-CoV-2 spike-specific IgG and IgA binding was measured using a lectin capture ELISA and compared between timepoints and correlated to neutralising titres. Findings: All 48 convalescent COVID-19 individuals were found to have detectable SARS-CoV-2 50% inhibitory dilution neutralisation titres (ID50) at baseline and 6 months post-symptom onset with mean ID50 of 1/943 and 1/411, respectively. SARS-CoV-2 neutralisation titres peaked within 1-2 months post-symptom onset. However, 50% of individuals showed comparable ID50 at baseline and 6 months post-symptom onset. Both SARS-CoV-2 spike-specific IgG and IgA levels correlated well with neutralising titres. IgG binding was found to be sustained up to 6 months post-symptom onset, whereas IgA levels declined. Interpretation: This study demonstrates durability of SARS-CoV-2 spike-specific IgG and neutralisation responses following recovery from mild COVID-19. Thus, all subjects included in this study might potentially have protective levels of neutralising antibodies 6 months post-symptom onset. This study also demonstrates a relationship between spike-specific IgA and neutralisation decline, with implications for long-term protection against SARS-CoV-2 infection. Funding: Novo Nordisk Foundation, Independent Research Fund Denmark and Danish Agency for Science and Higher Education.
| Originalsprog | Engelsk |
|---|---|
| Artikelnummer | 103519 |
| Tidsskrift | EBioMedicine |
| Vol/bind | 71 |
| ISSN | 2352-3964 |
| DOI | |
| Status | Udgivet - 2021 |
Bibliografisk note
Funding Information:
We thank all the participants for their contribution to this study. We would also like to thank Susanne Ruszcycka and Greta Vizgirda, Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, Denmark, for sample processing. Thanks to Sofie Dikeledi Kold Jespersen and Caroline Nørløv Vinten and Magnus Illum Dalegaard, Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, Denmark, for blood sampling and REDCap data recording, respectively. We thank Markus Hoffman, University of Göttingen, Germany, for provision of the codon optimized cloned spike sequence. This work was supported by grants from The Capital Region of Denmark's Research Foundation [C.S., J.B.], the Novo Nordisk Foundation [N.W., J.B.], the Independent Research Fund Denmark [J.B.], the Candys Foundation (C.F-A., S.R., J.B.), The Danish Cancer Society (J.B.), Manufacturer Vilhelm Pedersen and wife's memorial scholarship (S.B), Master carpenter Jørgen Holm and wife Elisa. F. Hansen's memorial scholarship (S.B) and the Danish Agency for Science and Higher Education (S.R., J.B.). J.B. is the 2015 recipient of the Novo Nordisk Prize and the 2019 recipient of a Distinguished Investigator grant from the Novo Nordisk Foundation.
Funding Information:
We thank all the participants for their contribution to this study. We would also like to thank Susanne Ruszcycka and Greta Vizgirda, Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, Denmark, for sample processing. Thanks to Sofie Dikeledi Kold Jespersen and Caroline N?rl?v Vinten and Magnus Illum Dalegaard, Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, Denmark, for blood sampling and REDCap data recording, respectively. We thank Markus Hoffman, University of G?ttingen, Germany, for provision of the codon optimized cloned spike sequence. This work was supported by grants from The Capital Region of Denmark's Research Foundation [C.S. J.B.], the Novo Nordisk Foundation [N.W. J.B.], the Independent Research Fund Denmark [J.B.], the Candys Foundation (C.F-A. S.R. J.B.), The Danish Cancer Society (J.B.), Manufacturer Vilhelm Pedersen and wife's memorial scholarship (S.B), Master carpenter J?rgen Holm and wife Elisa. F. Hansen's memorial scholarship (S.B) and the Danish Agency for Science and Higher Education (S.R. J.B.). J.B. is the 2015 recipient of the Novo Nordisk Prize and the 2019 recipient of a Distinguished Investigator grant from the Novo Nordisk Foundation.
Publisher Copyright:
© 2021
Antal downloads er baseret på statistik fra Google Scholar og www.ku.dk
ID: 278482350